U.S. markets close in 5 hours 39 minutes
  • S&P 500

    4,453.48
    -2.00 (-0.04%)
     
  • Dow 30

    35,058.04
    +260.04 (+0.75%)
     
  • Nasdaq

    14,947.68
    -100.02 (-0.66%)
     
  • Russell 2000

    2,268.35
    +20.27 (+0.90%)
     
  • Crude Oil

    75.24
    +1.26 (+1.70%)
     
  • Gold

    1,755.40
    +3.70 (+0.21%)
     
  • Silver

    22.75
    +0.33 (+1.47%)
     
  • EUR/USD

    1.1711
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.4750
    +0.0150 (+1.03%)
     
  • GBP/USD

    1.3727
    +0.0046 (+0.34%)
     
  • USD/JPY

    110.8130
    +0.1280 (+0.12%)
     
  • BTC-USD

    43,503.39
    +308.40 (+0.71%)
     
  • CMC Crypto 200

    1,083.62
    -17.90 (-1.62%)
     
  • FTSE 100

    7,061.78
    +10.30 (+0.15%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

SOPHiA GENETICS to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON and LAUSANNE, Switzerland, Aug. 30, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

SOPHiA GENETICS’ management is scheduled to present on Friday, September 10th at 9:30 a.m. Eastern Time/3:30 p.m. Central European Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: ir.sophiagenetics.com.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

Availability of Other Information About SOPHiA GENETICS:

Investors and others should note that SOPHiA GENETICS communicates with its investors and the public using its company website (SOPHiAGENETICS.COM) as well as other channels, including but not limited to U.S. Securities and Exchange Commission filings, press releases, presentations, public conference calls and webcasts. The information SOPHiA GENETICS communicates through these channels could be deemed to be material information. As a result, SOPHiA GENETICS encourages investors and others interested in SOPHiA GENETICS to review the information it disseminates through these channels on a regular basis.

Investor Contact:
Carrie Mendivil
carrie@gilmartinir.com

Media Contact:
sophiagenetics@consortpartners.com